New drug tarlatamab targets Hard-to-Treat brain tumors
NCT ID NCT06776250
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests tarlatamab, a drug that helps immune cells attack tumor cells, in 44 adults with recurrent IDH-mutant gliomas (a type of brain tumor). The study aims to see if tarlatamab can increase immune cell activity in the tumor and potentially control the disease. Participants must have had up to two prior treatments and be eligible for surgery or biopsy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tarlatamab
What this could lead to
If successful, this could point toward a new treatment option for people with recurrent IDH-mutant gliomas, potentially helping to control tumor growth.
What could go wrong
This is an early phase 2 trial with only 44 participants, so results may not apply to everyone. The drug's effectiveness and safety in the brain are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OLIGODENDROGLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact